# natureresearch

Corresponding author(s): Erol Fikrig

Last updated by author(s): Jan 18, 2019

# **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

### Statistics

| For         | all st      | atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.   |
|-------------|-------------|---|
| n/a         | Cor         | firmed  |
|             |             | The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement   |
|             | $\square$   | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |
|             |             | The statistical test(s) used AND whether they are one- or two-sided<br>Only common tests should be described solely by name; describe more complex techniques in the Methods section.   |
| $\boxtimes$ |             | A description of all covariates tested  |
|             |             | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |
|             |             | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)<br>AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
|             | $\boxtimes$ | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.                           |
| $\boxtimes$ |             | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| $\boxtimes$ |             | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| $\boxtimes$ |             | Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  |
|             | I           | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.   |
|             |             |   |

## Software and code

| Policy information about availability of computer code |   |  |  |  |
|--|---|--|--|--|
| Data collection  | FACSDiva for collection   |  |  |  |
| Data analysis  | Prism7, Partek flow (v7.0) and FlowJo (version 10) for analysis |  |  |  |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

### Data

Life sciences

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets

- A list of figures that have associated raw data

- A description of any restrictions on data availability

Data available from the authors on request.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

| Sample size     | No sample-size calculations were performed. Sample size was determined to be adequate based on the magnitude and consistency of measurable differences between groups.           |
|-----------------|--|
| Data exclusions | On principle, data were only excluded for failed experiments, reasons for which included poor mosquito-feeding.  |
| Replication     | Replicate experiments were successful.   |
| Randomization   | No randomization of mice and mosquitoes.   |
| Blinding        | Investigators were not blinded to mouse treatment during experiments. Data reported for in vitro and in vivo experiments are not subjective but rather based on all experiments. |

#### All studies must disclose on these points even when the disclosure is negative.

# Reporting for specific materials, systems and methods

Methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

#### Materials & experimental systems

|             |                             | -           |                        |
|-------------|-----------------------------|-------------|------------------------|
| n/a         | Involved in the study       | n/a         | Involved in the study  |
|             | Antibodies                  | $\boxtimes$ | ChIP-seq               |
|             | Eukaryotic cell lines       |             | Flow cytometry         |
| $\boxtimes$ | Palaeontology               | $\boxtimes$ | MRI-based neuroimaging |
|             | Animals and other organisms |             |                        |
| $\boxtimes$ | Human research participants |             |                        |
| $\boxtimes$ | Clinical data               |             |                        |
|             |                             |             |                        |

### Antibodies

| Antibodies used | For IMC, CD3 (170Er - Polyclonal, C-Terminal), CD11b (149Sm - EPR1344), MHCII(174Yb - M5/114.15.2) and Ly6G (141Pr – 1A8) purchased from Fluidigm.<br>For FACS, CD45 (PerCP - BD Pharmingen; Clone 30-F11), MHCII (APC-Cy7 – Biolegend; Clone M4/114.15.2), CD11b (PE – Biolegend; Clone M1/70), CD11c (PE-Cy7 – BD Pharmingen; Clone HL3), and Ly6G (FITC – Tonbo; Clone RB6-8C5)<br>For immunoblot, anti-actin (Abcam; rabbit polyclonal antibody) |
|-----------------|--|
| Validation      | The validation data of each antibodies can be accessed from each company website.  |

### Eukaryotic cell lines

| Policy information about <u>cell lines</u>                  |  |
|---|--|
| Cell line source(s)   | C6/36 Aedes albopictus cells (ATCC), Vero cells (African green monkey kidney epithelial cells) (ATCC), S2 (Drosophila) cells |
| Authentication  | No authentication has been used.   |
| Mycoplasma contamination                                    | These cells have been routinely confirmed to be mycoplasma free.   |
| Commonly misidentified lines<br>(See <u>ICLAC</u> register) | No cell lines used are listed in the database of commonly misidentified cell lines.  |

### Animals and other organisms

| Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research |   |  |  |  |
|---|---|--|--|--|
| Laboratory animals  | Description of research mice and mosquitoes used for experiments can be found in the relevant figure legends and Methods. |  |  |  |
| Wild animals  | This study did not involve wild animals.  |  |  |  |
| Field-collected samples   | This study did not involve samples collected from the field.  |  |  |  |

All experiments were performed in accordance with guidelines from the Guide for the Care and Use of Laboratory Animals of the NIH. The animal experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the Yale University School of Medicine (Assurance number A3230-01).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Flow Cytometry

#### Plots

Confirm that:

 $\bigotimes$  The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

 $\square$  All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

| Sample preparation        | Sample preparation listed in Methods   |
|---------------------------|--|
| Instrument                | LSR II and Stratedigm  |
| Software                  | FACSDiva for collection and FlowJo (version 10) for analysis   |
| Cell population abundance | About 0.5-1 million cells were harvested from one mouse ear. The dead cells were excluded by staining with Live/Dead staining kit. |
| Gating strategy           | Relevant gating strategies shown in Supplementary Information  |
|                           |  |

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.